The evolution of clinical diagnosis and treatment of castration-resistant prostate cancer from the updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 / 中华泌尿外科杂志
Chinese Journal of Urology
; (12): 884-888, 2022.
Article
em Zh
| WPRIM
| ID: wpr-993942
Biblioteca responsável:
WPRO
ABSTRACT
Castration-resistant prostate cancer (CRPC) is an important research focus in the field of prostate cancer. The adjustment of its diagnosis criteria also directly impacts the clinical diagnosis and treatment practice, as well as the design and implementation of the relevant clinical trials. The Prostate Cancer Clinical Trials Working Group (PCWG) has published several consensuses to provide further reference in clinical practice and trials design. In PCWG3, the recommended PSA cut-off value to confirmed CRPC diagnosis was further lowered from 2 ng / ml to 1 ng/ml. The update of PCWG3 may have a profound impact on the clinical diagnosis, treatment and trials design of prostate cancer in the future.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Urology
Ano de publicação:
2022
Tipo de documento:
Article